DiaMedica Therapeutics (DMAC) Competitors $4.03 -0.09 (-2.18%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$4.03 0.00 (0.00%) As of 06/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAC vs. DAWN, VIR, AVXL, ABUS, EOLS, KALV, ANAB, COGT, ABCL, and TRVIShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Day One Biopharmaceuticals (DAWN), Vir Biotechnology (VIR), Anavex Life Sciences (AVXL), Arbutus Biopharma (ABUS), Evolus (EOLS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Cogent Biosciences (COGT), AbCellera Biologics (ABCL), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Its Competitors Day One Biopharmaceuticals Vir Biotechnology Anavex Life Sciences Arbutus Biopharma Evolus KalVista Pharmaceuticals AnaptysBio Cogent Biosciences AbCellera Biologics Trevi Therapeutics Day One Biopharmaceuticals (NASDAQ:DAWN) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Which has preferable earnings & valuation, DAWN or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Day One Biopharmaceuticals. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than DiaMedica Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDay One Biopharmaceuticals$161.92M4.23-$188.92M-$0.71-9.51DiaMedica TherapeuticsN/AN/A-$19.38M-$0.64-6.30 Does the MarketBeat Community favor DAWN or DMAC? DiaMedica Therapeutics received 39 more outperform votes than Day One Biopharmaceuticals when rated by MarketBeat users. However, 70.89% of users gave Day One Biopharmaceuticals an outperform vote while only 62.91% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformDay One BiopharmaceuticalsOutperform Votes5670.89% Underperform Votes2329.11% DiaMedica TherapeuticsOutperform Votes9562.91% Underperform Votes5637.09% Do institutionals & insiders have more ownership in DAWN or DMAC? 87.9% of Day One Biopharmaceuticals shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 6.2% of Day One Biopharmaceuticals shares are held by company insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, DAWN or DMAC? Day One Biopharmaceuticals has a beta of -1.3, indicating that its share price is 230% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Is DAWN or DMAC more profitable? Day One Biopharmaceuticals' return on equity of -22.40% beat DiaMedica Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Day One BiopharmaceuticalsN/A -22.40% -19.79% DiaMedica Therapeutics N/A -43.67%-40.81% Do analysts prefer DAWN or DMAC? Day One Biopharmaceuticals currently has a consensus target price of $30.57, suggesting a potential upside of 352.91%. DiaMedica Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 98.51%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Day One Biopharmaceuticals is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor DAWN or DMAC? In the previous week, Day One Biopharmaceuticals had 1 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 3 mentions for Day One Biopharmaceuticals and 2 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.43 beat Day One Biopharmaceuticals' score of 0.38 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Day One Biopharmaceuticals Neutral DiaMedica Therapeutics Neutral SummaryDay One Biopharmaceuticals beats DiaMedica Therapeutics on 11 of the 17 factors compared between the two stocks. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$172.82M$6.85B$5.57B$8.62BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-7.208.7827.1720.06Price / SalesN/A255.64409.72157.10Price / CashN/A65.8538.2534.64Price / Book2.996.557.064.70Net Income-$19.38M$143.93M$3.23B$247.88M7 Day Performance-1.47%3.97%2.89%2.66%1 Month Performance5.22%11.32%9.06%6.40%1 Year Performance60.56%4.20%31.40%14.07% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics1.3602 of 5 stars$4.03-2.2%$8.00+98.5%+54.4%$172.82MN/A-7.2020Short Interest ↑DAWNDay One Biopharmaceuticals1.7291 of 5 stars$7.01+9.9%$30.57+336.1%-46.2%$710.55M$161.92M-6.8160VIRVir Biotechnology3.0632 of 5 stars$5.07+2.6%$32.86+548.1%-50.6%$700.87M$14.30M-1.29580Positive NewsAVXLAnavex Life Sciences3.9111 of 5 stars$7.56+0.4%$44.00+482.0%+121.6%$645.41MN/A-13.7540Positive NewsABUSArbutus Biopharma2.2275 of 5 stars$3.36flat$5.50+63.7%+10.1%$643.53M$6.40M-7.8190Positive NewsEOLSEvolus4.115 of 5 stars$9.97+8.5%$23.75+138.2%-11.6%$642.83M$275.46M-10.96170Positive NewsInsider TradeGap UpHigh Trading VolumeKALVKalVista Pharmaceuticals3.9493 of 5 stars$12.92+9.5%$24.83+92.2%+10.5%$642.33MN/A-3.55100Positive NewsInsider TradeAnalyst RevisionHigh Trading VolumeANABAnaptysBio1.7422 of 5 stars$21.86-1.7%$40.38+84.7%-0.2%$642.25M$111.87M-3.60100COGTCogent Biosciences2.487 of 5 stars$5.61+3.1%$14.57+159.7%-17.7%$638.73MN/A-2.2680Positive NewsHigh Trading VolumeABCLAbCellera Biologics2.487 of 5 stars$2.14+5.9%$8.33+289.4%-5.8%$638.63M$23.11M-3.51500Options VolumeGap UpTRVITrevi Therapeutics3.5 of 5 stars$6.32-2.9%$18.63+194.7%+140.4%$631.32MN/A-14.3620High Trading Volume Related Companies and Tools Related Companies Day One Biopharmaceuticals Alternatives Vir Biotechnology Alternatives Anavex Life Sciences Alternatives Arbutus Biopharma Alternatives Evolus Alternatives KalVista Pharmaceuticals Alternatives AnaptysBio Alternatives Cogent Biosciences Alternatives AbCellera Biologics Alternatives Trevi Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DMAC Stock Free DMAC Stock Alerts